Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OpGen Inc OPGN

Healthcare Biotechnology
OpGen, Inc. is a precision medicine company that uses molecular diagnostics and informatics to combat infectious diseases. The Company distributes molecular microbiology solutions that help guide clinicians with more information about life threatening infections to improve patient outcomes and decrease the spread of infections caused by multidrug-resistant microorganisms (MDROs). The Company's... see more

Recent & Breaking News (OTCPK:OPGN)

OpGen Announces Interim Analysis Results from Clinical Trial for Unyvero Urinary Tract Infection Panel

GlobeNewswire April 5, 2022

OpGen Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire March 29, 2022

OpGen to Provide Business Update and Financial Results for the Fourth Quarter and Full Year 2021 on March 29th at 4:30 p.m. Eastern Time

GlobeNewswire March 15, 2022

OpGen Announces Publication of Results from the Acuitas AMR Gene Panel Multicenter Clinical Trial in the Journal of Clinical Microbiology

GlobeNewswire February 10, 2022

OpGen Announces Successful Completion of Unyvero A30 Development Milestone

GlobeNewswire February 10, 2022

OpGen to Participate in Edison Group's Global Healthcare "Open House" Virtual Conference from January 25-27th, 2022

GlobeNewswire January 18, 2022

OpGen Announces Preliminary Unaudited Revenue for Fiscal 2021 and Provides Business Update

GlobeNewswire January 10, 2022

OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents

GlobeNewswire December 14, 2021

OpGen Announces Results of Special Meeting of Stockholders

GlobeNewswire December 8, 2021

OpGen Subsidiary Ares Genetics Announces Strategic Database Access Transaction

GlobeNewswire November 30, 2021

OpGen Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 11, 2021

OpGen Appoints Albert Weber as Chief Financial Officer

GlobeNewswire November 4, 2021

OpGen Announces Special Meeting of Stockholders to Vote on Proposed Increase to Number of Authorized Shares of Common Stock

GlobeNewswire November 4, 2021

OpGen to Provide Business Update and Financial Results for the Third Quarter 2021 on November 11th at 4:30 p.m. Eastern Time

GlobeNewswire October 28, 2021

OpGen Subsidiary Ares Genetics Launches AREScloud

GlobeNewswire October 21, 2021

OpGen Announces Closing of $15 Million Registered Direct Offering

GlobeNewswire October 18, 2021

OpGen Announces $15 Million Registered Direct Offering

GlobeNewswire October 14, 2021

OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel

GlobeNewswire October 4, 2021

OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021

GlobeNewswire October 4, 2021

OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel

GlobeNewswire September 30, 2021